Exclusion criteria. حسب Nameer Ascandar (15449218)

الموضوعات:

Trends in the monthly volume of cardiac device infection and removal. حسب Nameer Ascandar (15449218)

الموضوعات:

Baseline patient, clinical, and hospital factors after admission for cardiac device infection during and prior to the COVID-19 pandemic. حسب Nameer Ascandar (15449218)

الموضوعات:

Unadjusted outcomes after admission for cardiac device infection; (+) COVID-19, infected with COVID-19 virus; (-) COVID-19, non-infected with COVID-19 virus. حسب Nameer Ascandar (15449218)

الموضوعات:

Unadjusted outcomes after admission for cardiac device infection during and prior to the COVID-19 pandemic. حسب Nameer Ascandar (15449218)

الموضوعات:

Baseline patient, clinical, and hospital factors after admission for cardiac device infection; (+) COVID-19, infected with COVID-19; (-) COVID-19, not infected with COVID-19. حسب Nameer Ascandar (15449218)

الموضوعات:

Factors associated with adjusted odds of major adverse events after admission for cardiac device infection; *<i>P<0</i>.<i>05</i>. حسب Nameer Ascandar (15449218)

الموضوعات:

Venn diagram illustrating volume distribution of device removal. حسب Nameer Ascandar (15449218)

الموضوعات:

Networks favouring more connected individuals results in a significant decrease to the likelihood of network recovery. حسب Adam Lee Miles (14123916)

CBP per cumulative year for daratumumab and pembrolizumab per vial. حسب R. J. S. D. Heine (17889199)

الموضوعات:

S4 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S1 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S5 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S3 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S6 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

CBP per cumulative indication for daratumumab and pembrolizumab per vial. حسب R. J. S. D. Heine (17889199)

الموضوعات:

Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. حسب R. J. S. D. Heine (17889199)

الموضوعات:

Implementation of indication-based pricing (10^th scenario) for daratumumab and pembrolizumab. حسب R. J. S. D. Heine (17889199)

الموضوعات:

Input parameters for the base-case analysis. حسب R. J. S. D. Heine (17889199)

الموضوعات:

S2 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات: